Pfizer global president joins NJOY as CEO

NJOY, an independent e-cigarette and vaping company, on Monday announced the appointment of Paul Sturman as its new CEO and president.

Sturman joins the company from Pfizer's consumer healthcare business where he served as global president and general manager. Sturman was responsible for the $3 billion division's global operations, which included development and marketing of such household brands as Advil, Centrum, Chapstick and Robitussin. Before joining Pfizer, he was president of Johnson & Johnson's North American consumer healthcare unit.

“NJOY has been a pioneer in the electronic cigarette category and I admire its noble mission of providing satisfying alternatives to combustion smoking, the leading cause of preventable death in the world,” Sturman said. “I couldn’t be more excited to lead this talented organization and leverage its top shelf R&D engine to accelerate growth and take the company to the next level. I believe NJOY is uniquely positioned to consistently deliver innovative, quality solutions for the millions of adult smokers, in a responsible and compliant manner.”

Dr. Richard Carmona, 17th U.S. Surgeon General and chairman on NJOY's scientific advisory board, added that he's "confident that Mr. Sturman has the ability and commitment to pursue making combustible tobacco obsolete. Doing so will reduce preventable, tobacco-caused, chronic disease — thereby improving the public's health while reducing the cost of health care."